Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits-Reference-Cited by-同舟云学术

Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits

Published:2017-10 Issue: Volume:265 Page:283-291
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Sudo Mitsumasa,Li Yuxin,Hiro Takafumi,Takayama Tadateru,Mitsumata Masako,Shiomi Masashi,Sugitani Masahiko,Matsumoto Taro^ORCID,Hao Hiroyuki,Hirayama Atsushi

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference51 articles.

1. The role of incretins in glucose homeostasis and diabetes treatment;Kim;Pharmacol. Rev.,2008

2. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S);Rosenstock;J. Diabetes Complicat.,2014

3. PDY6797 investigators, Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin;Seino;Diabetes Obes. Metab.,2014

4. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy;Nikolaidis;Circulation,2004

5. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion;Nikolaidis;Circulation,2004

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incretin-based therapy: a new horizon in diabetes management;Journal of Diabetes & Metabolic Disorders;2024-08-17

2. Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs;Journal of Clinical Medicine;2024-08-09

3. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage;American Journal of Physiology-Heart and Circulatory Physiology;2024-05-01

4. The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis;Diabetes, Obesity and Metabolism;2024-03-21

5. Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?;Nature Cardiovascular Research;2023-07-13